Who Paid My Doc
A Phase 3 Study to Evaluate the Effects of Chenodal in Adult and Pediatric Patients With Cerebrotendinous Xanthomatosis (Restore)
Research payments
$568,994
Through program year 2024, $568,994 in research payments was reported against A Phase 3 Study to Evaluate the Effects of Chenodal in Adult and Pediatric Patients With Cerebrotendinous Xanthomatosis (Restore), across 26 payments, paid by Mirum Pharmaceuticals, Inc..
- Paid by
- Mirum Pharmaceuticals, Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $552,225 | 18 |
| 2023 | Research | $16,770 | 8 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
6 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.